Before you begin

Course Pre-Test

Ten items covering the diagnostic standard, formulation selection, monitoring, and fertility. This pre-test is a baseline only — it is not scored for contact hours and you can review the rationales immediately. Credit is awarded on the post-test.

1
What is the minimum testing required to establish a diagnosis of testosterone deficiency in a symptomatic adult man?
One total testosterone drawn at any time of dayTwo low early-morning fasting total testosterone values on separate daysA single free testosterone by immunoassayA symptom questionnaire plus a single random level
2
An LH of 1.2 IU/L and FSH of 1.8 IU/L with a total testosterone of 180 ng/dL indicates:
Primary hypogonadismSecondary (hypogonadotropic) hypogonadismNormal axis functionAndrogen insensitivity
3
Which condition LOWERS sex hormone-binding globulin, making total testosterone underestimate the bioavailable fraction?
HyperthyroidismObesity with insulin resistanceCirrhosisAging
4
A 34-year-old man with confirmed hypogonadism wants children within two years. What is the most appropriate management?
Start testosterone cypionate and reassess fertility laterStart a testosterone gel because transdermals do not suppress spermatogenesisAvoid testosterone monotherapy; obtain a semen analysis and refer for fertility-sparing managementStart testosterone with a concurrent aromatase inhibitor to preserve fertility
5
Hematocrit on therapy reaches 55%. The guideline-concordant action is to:
Continue therapy and recheck in one yearHold or reduce the dose, evaluate for sleep apnea and other causes, and consider therapeutic phlebotomyAdd an aromatase inhibitorIncrease the dosing interval to monthly injections
6
Which formulation carries a boxed warning for secondary exposure of women and children?
Testosterone cypionate (Depo-Testosterone)Testosterone transdermal gel (AndroGel)Testosterone pellets (Testopel)Testosterone undecanoate oral (Jatenzo)
7
The TRAVERSE trial (2023) primarily demonstrated that testosterone therapy in men with hypogonadism and cardiovascular risk:
Reduced major adverse cardiovascular eventsWas noninferior to placebo for major adverse cardiovascular eventsDoubled the rate of myocardial infarctionHad no measurable effect on any outcome
8
When should a trough testosterone level be drawn for a man on weekly testosterone cypionate?
24 hours after the injectionImmediately before the next scheduled injectionAt any point in the weekThree days after the injection
9
A man on therapy develops tender gynecomastia with an elevated estradiol. The first-line response is to:
Add anastrozole indefinitelyReduce the testosterone dose or shorten the interval to lower peak exposureDiscontinue therapy permanentlyOrder a testicular ultrasound
10
Which PSA change on therapy meets the threshold for urology referral?
Any measurable rise from baselineA rise greater than 1.4 ng/mL within 12 monthsA rise greater than 0.2 ng/mL within 12 monthsPSA does not require monitoring on therapy

0 of 10 answered